Sarepta Therapeutics (SRPT) Short term Debt (2010 - 2025)

Sarepta Therapeutics' Short term Debt history runs 12 years deep, the most recent figure standing at $36.0 million for Q3 2025.

• In Q3 2025, Short term Debt fell 60.7% year-over-year to $36.0 million; the TTM figure through Sep 2025 stood at $36.0 million (down 60.7% YoY), while the FY2023 annual figure was $105.5 million, changed N/A from the prior year.
• Short term Debt for Q3 2025 stood at $36.0 million, down from $91.6 million in the prior quarter.
• The five-year high for Short term Debt was $105.6 million in Q1 2024, with the low at $36.0 million in Q3 2025.
• The 3-year median for Short term Debt is $91.6 million (2024), against an average of $86.0 million.
• Peak annual rise in Short term Debt reached 60.7% in 2025, while the deepest fall reached 60.7% in 2025.
• Sarepta Therapeutics' Short term Debt stood at $105.5 million in 2023, then declined by 13.17% to $91.6 million in 2024, then tumbled by 60.7% to $36.0 million in 2025.
• Business Quant data shows SRPT's Short term Debt at $36.0 million in Q3 2025, $91.6 million in Q3 2024, and $91.5 million in Q2 2024.